《大行報告》瑞信上調潤啤(00291.HK)目標價至82元 評級「跑贏大市」
瑞信發表報告,指華潤啤酒(00291.HK)發盈喜,上半年股東應佔溢利較2020年同期增加至少100%,當中包括出讓其擁有的地塊收取初始稅後補償收益約13億元人民幣,估算經常性盈利增35%,勝預期。
該行相信華潤啤酒的超高端品牌銷售增長超預期,毛利率料有穩定擴張,經營開支亦具紀律。該行認爲,公司未來數年超高端品牌年複合增長率可達20%,公司近期亦升至2025年預期25%。
瑞信列華潤啤酒爲行業首選股,目標價由80元升至82元,重申「跑贏大市」評級,上調對其今明兩年每股盈利預測各4%及3.7%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.